Study to Evaluate the Food Effect of TP-05 in Healthy Participants

Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation including medical history and physical examination * Participants who are non- or ex-smokers * No clinically significant disease captuired in medical history or evidence of clinically significant findings on the physical examination and/or ECG at Screening and Day -1, as determined by the Investigator * BMI 18.5-29.9 kg/m2 (inclusive) and weighs at least 50.0 kg at Screening * Ability to comply with contraceptive requirements Exclusion Criteria: * Female who is breast-feeding or pregnancy according to the serum pregnancy test at Screening and urine pregnancy test at Day -1 prior to study drug administration * History of significant hypersensitivity to lotilaner or any related products * History of significant gastrointestinal, metabolic, liver, or kidney disease, or surgery that may affect drug bioavailability * History of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic, or dermatologic disease * History of malignancy (or active malignancy), with the exception of treated basal cell or squamous cell carcinoma * Positive test results for HIV-1/HIV-2 antigen/antibody, Hepatitis B surface antigen (HBsAg) or Hepatitis C virus antibody (HCVAb) * Positive result for SARS-CoV-2 testing at Day -1 * Use of any non-prescription or prescription drugs in the 7 days or 5 half-lives (whichever is longer) prior to study drug administration and through the treatment period of the study * Treatment with an investigational drug within 30 days or 5 times the half-life (whichever is longer) prior to Screening and through Day 60 of the study * History of live attenuated vaccine within 4 weeks prior to study drug administration or requirement to receive these vaccinations through Day 60 of the study * Plasma donation within 7 days prior to Screening through Day 60 of the study * Blood donation or significant blood loss approximately 500 mL within 56 days prior to Screening through Day 60 of the study